Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey
Japanese Journal of Clinical Oncology · 2023
DOI: 10.1093/jjco/hyac180 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2023. Verfasst von Hidemasa Kawamura und 19 weiteren Autor:innen. Beteiligte Einrichtung: Gunma University Heavy Ion Medical Center, Maebashi, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiation Oncology, Carcinoma, Ductal. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
The clinical characteristics of prostate ductal carcinoma is still unclear, and treatment strategy has not yet been established due to its rarity. Therefore, we conducted a multicenter survey of radiation therapy for prostate ductal carcinoma in Japan.
Method
Data of patients with ductal carcinoma of the prostate treated with radiation therapy between 1996 and 2018 were extracted from the database of each facility.
Results
Fifty-two treatment records of 41 patients were collected from nine institutions. The treatment purpose and situations were varied curative intent to palliation. Twenty-eight patients received curative treatments. The median follow-up period of these patients was 68 months. Androgen deprivation therapy was combined with radiation therapy in 26 cases (93%). X-ray and particle irradiation was used. Radiation dose range was 63–78 Gy; 5-year overall survival, progression-free survival and biochemical relapse-free survival were 87.0, 79.3 and 79.3%, respectively. One patient experienced Grade 3 radiation proctitis and one experienced Grade 3 radiation cystitis. There were no Grade 4 or worse adverse events.
Conclusion
Most patient received similar treatment with adenocarcinoma of prostate, and the clinical results were compatible. For more reliable evidence, further studies are required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gunma University Heavy Ion Medical Center, Maebashi, Japan.
- Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Department of Radiation Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Radiation Oncology, Kurashiki Central Hospital, Okayama, Japan.
- Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Oncology Center, Hidaka Hospital, Takasaki, Japan.
ORCID-Profile: Hidemasa Kawamura
Zitieren
APA
Kawamura, H., Nakamura, K., Yoshioka, Y., Itasaka, S., Tomita, N., Onishi, M., Iwata, H., Aizawa, T., Kikuchi, K., Nagata, K., Nakamura, K., Nishioka, K., Ishiyama, H., Ueno, S., Kokubo, M., Yamazaki, H., Watanabe, K., Toyoda, T., Akimoto, T., & JROSG Working Subgroup of Urologic Oncology (2023). Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyac180
Vancouver
Kawamura H, Nakamura K, Yoshioka Y, Itasaka S, Tomita N, Onishi M, et al. Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey. Japanese Journal of Clinical Oncology. 2023. doi:10.1093/jjco/hyac180
BibTeX
@article{Kawamura2023,
author = {Kawamura, Hidemasa and Nakamura, Katsumasa and Yoshioka, Yasuo and Itasaka, Satoshi and Tomita, Natsuo and Onishi, Masahiro and Iwata, Hiromitsu and Aizawa, Takuya and Kikuchi, Koyo and Nagata, Kenji and Nakamura, Kiyonao and Nishioka, Kentaro and Ishiyama, Hiromichi and Ueno, Shuichi and Kokubo, Masaki and Yamazaki, Hideya and Watanabe, Kenta and Toyoda, Tatsuya and Akimoto, Tetsuo and JROSG Working Subgroup of Urologic Oncology, JROSG Working Subgroup of Urologic Oncology},
title = {Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey},
journal = {Japanese Journal of Clinical Oncology},
year = {2023},
doi = {10.1093/jjco/hyac180}
}
EUVIMED